COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Patel, Ankit; Verma, Ashish

doi:10.1001/jama.2020.4812

Cited by 399 publications

(415 citation statements)

References 7 publications

Supporting

Mentioning

382

Contrasting

Unclassified

Order By: Relevance

“…ACE inhibitors are commonly used in COVID-19 patients with comorbidities of hypertension, diabetes mellitus, and coronary heart diseases (Fang et al, 2020, Ferrario et al, 2005, indicating to physicians that patients on these medications may be more susceptible to SARS-CoV-2 infection. Indeed, since epidemiological studies have reported increased mortality and morbidity in COVID-19 patients with hypertension, more research needs to be done to address other confounding variables including other comorbidities and treatment with ACE inhibitors or angiotensin receptor blockers (Patel and Verma, 2020).…”

Section: Discussionmentioning

confidence: 99%

Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions

Butler

Mozsary

Meydan

et al. 2020

Preprint

View full text Add to dashboard Cite

The pandemic from the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) led to hundreds of thousands of deaths, including >15,000 in New York City (NYC). This pandemic highlighted a pressing clinical and public health need for rapid, scalable diagnostics that can detect SARS-CoV-2 infection, interrogate strain evolution, and map host response in patients. To address these challenges, we designed a fast (30 minute) colorimetric test to identify SARS-CoV-2 infection and simultaneously developed a large-scale shotgun metatranscriptomic profiling platform for nasopharyngeal swabs. Both technologies were used to profile 338 clinical specimens tested for SARS-CoV-2 and 86 NYC subway samples, creating a broad molecular picture of the COVID-19 epidemic in NYC. Our results nominate a novel, NYC-enriched SARS-CoV-2 subclade, reveal specific host responses in ACE pathways, and find medication risks associated with SARS-CoV-2 infection and ACE inhibitors. Our findings have immediate applications to SARS-CoV-2 diagnostics, public health monitoring, and therapeutic development.

show abstract

Section: Discussionmentioning

confidence: 99%

Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions

Butler

Mozsary

Meydan

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are apparently required for the normalization of the abnormally high level of Angiotensin II patients with COVID-19 [9]. However, no consensus has yet been reached about the use of ACEI and ARB in patients with COVID-19 [34]. The other challenge is that whereas the 2019-nCoV is isolated from the host and grown in host cells, there is no animal model of disease to judge the condition is caused by 2019-nCoV [35].…”

Section: Expert Opinionmentioning

confidence: 99%

Immune-epidemiological parameters of the novel coronavirus – a perspective

Saghazadeh

Rezaei

2020

Expert Review of Clinical Immunology

203

183

View full text Add to dashboard Cite

“…4,15,16 The role of ACEI and ARB in COVID-19 infection remains controversial -as the data is not adjusted for confounding factors of age and other comorbidities to definitively show that ACEI or ARB are independently associated with worse outcomes -and of course, this does not show causality either. 17 Hence, various independent medical societies have put out position statements that recognize the potential risks but given the current quality of evidence, recommend against inappropriate cessation or switch from ACEI/ARB therapy for hypertension, given its proven benefits. 18,19 Therefore, the objective of this study was to investigate the role of several adjuvant treatments in preventing severe pneumonia in COVID-19 patients from seven cities in Hunan province, China.…”

Section: Introductionmentioning

confidence: 99%

The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis

Feng

Yao

et al. 2020

Preprint

View full text Add to dashboard Cite

medRxiv preprint KEYPOINTS Question: Does the use of adjuvant therapy reduce progression to severe pneumonia in patients with coronavirus disease 2019 (COVID-19)?Findings: In this retrospective, observational cohort study involving 564 patients with confirmed COVID-19, hypertension was an independent risk factor for progression to severe pneumonia irrespective of age and those on angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy were less likely to develop severe COVID-19 pneumonia, while nonspecific antivirals or chloroquine did not have significant impact on clinical progression. ABSTRACT IMPORTANCE Coronavirus disease 2019 (COVID-19) is a global pandemic associated with high mortality and effective treatment to prevent clinical deterioration to severe pneumonia has not yet been well clarified. OBJECTIVE To investigate the role of several adjuvant treatments in preventing severe pneumonia in patients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS Multicenter, retrospective cohort study of 564 consecutively hospitalized patients with confirmed COVID-19 at Third EXPOSURES Nonspecific antivirals (arbidol, lopinavir/ritonavir, and interferon α ), antihypertensives, and chloroquine. MAIN OUTCOMES AND MEASURES The development of severe COVID-19 pneumonia; Demographic, epidemiological, clinical, laboratory, radiological, and treatment data were collected and analyzed. RESULTSOf 564 patients, the median age was 47 years (interquartile range, 36-58 years), and 284 (50.4%) patients were men. Sixty-nine patients (12.2%) developed severe pneumonia.Patients who developed severe pneumonia were older (median age of 59 and 45 years, respectively), and more patients had comorbidities including hypertension (30.4% and 12.3%,

show abstract

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Cited by 399 publications

References 7 publications

Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions

Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions

Immune-epidemiological parameters of the novel coronavirus – a perspective

The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis

Contact Info

Product

Resources

About